| Year | Citation | Score | |||
|---|---|---|---|---|---|
| 2019 | Ho KA, Acar M, Puig A, Hutas G, Fifer S. What do Australian patients with inflammatory arthritis value in treatment? A discrete choice experiment. Clinical Rheumatology. PMID 31858340 DOI: 10.1007/S10067-019-04843-4 | 0.316 | |||
| 2011 | Nagyeri G, Radacs M, Ghassemi-Nejad S, Tryniszewska B, Olasz K, Hutas G, Gyorfy Z, Hascall VC, Glant TT, Mikecz K. TSG-6 protein, a negative regulator of inflammatory arthritis, forms a ternary complex with murine mast cell tryptases and heparin. The Journal of Biological Chemistry. 286: 23559-69. PMID 21566135 DOI: 10.1074/Jbc.M111.222026 | 0.341 | |||
| 2010 | Hutas G. Golimumab as the first monthly subcutaneous fully human anti-TNF-alpha antibody in the treatment of inflammatory arthropathies. Immunotherapy. 2: 453-60. PMID 20635999 DOI: 10.2217/Imt.10.34 | 0.328 | |||
| 2008 | Hutas G. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies. Current Opinion in Investigational Drugs (London, England : 2000). 9: 1206-15. PMID 18951300 | 0.371 | |||
| 2008 | Hutás G, Bajnok E, Gál I, Finnegan A, Glant TT, Mikecz K. CD44-specific antibody treatment and CD44 deficiency exert distinct effects on leukocyte recruitment in experimental arthritis. Blood. 112: 4999-5006. PMID 18815286 DOI: 10.1182/Blood-2008-04-150383 | 0.345 | |||
| 2008 | Hutas G. Golimumab, a fully human monoclonal antibody against TNFalpha. Current Opinion in Molecular Therapeutics. 10: 393-406. PMID 18683105 | 0.346 | |||
| 2007 | O'Neill SK, Cao Y, Hamel KM, Doodes PD, Hutas G, Finnegan A. Expression of CD80/86 on B cells is essential for autoreactive T cell activation and the development of arthritis. Journal of Immunology (Baltimore, Md. : 1950). 179: 5109-16. PMID 17911596 DOI: 10.4049/Jimmunol.179.8.5109 | 0.314 | |||
| Show low-probability matches. | |||||